# Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)

> **NCT01069861** · PHASE2 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 4 (actual)

## Conditions studied

- PPHN
- Persistent Pulmonary Hypertension of the Newborn
- Hypoxic Respiratory Failure

## Interventions

- **DRUG:** sildanefil

## Key facts

- **NCT ID:** NCT01069861
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069861, "Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01069861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*